The cash deal will add an experimental drug for moderate to severe atopic dermatitis, building up AbbVie’s core business.

Daejin Abidoye On AbbVie's Mission: "Finding the Right Patient for the Right Drug at the Right Time" ...

In this week’s edition of InnovationRx, we look at AbbVie’s new megadeal, an agentic AI startup saving Medicare $2 million a ...

AbbVie’s largest deal in more than half a decade adds a group of immune disease medications — among them a Dupixent ...

The company is already renowned by many as a giant in the segment.

Humira plan is working brilliantly, but a subtle shift in the growth rate of one of its two key drugs deserves a much closer ...

By Padmanabhan Ananthan June 22 (Reuters) - AbbVie said on Monday it would buy Apogee Therapeutics for $10.9 billion, the ...

The pharmaceutical company gains a prospective blockbuster with the deal, but is it worth $10.9 billion?

An intriguing acquisition could bring exciting new drugs into the medicine maker's development pipeline.

AbbVie (NYSE:ABBV | ABBV Price Prediction) has quietly become one of healthcare’s most underrated growth stories. CEO Robert ...

The drugmaker has successfully replaced its former blockbuster, but buying into that victory today means paying a steep ...

Pharmaceutical maker AbbVie said the Food and Drug Administration approved its Skyrizi to treat pediatric patients with psoriasis. Skyrizi, or risankizumab-rzaa, will be available to patients aged six ...